Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 4, 2004 - Issue 6
Submit an article Journal homepage
27
Views
10
CrossRef citations to date
0
Altmetric
Review

Treatment of muscle-invasive bladder cancer: progress and new challenges

Judi C Herring University of Florida, Division of Urology, Department of Surgery, 555 West Eighth Street, Pavilion, 2 South, Jacksonville, FL 32209, USA. [email protected]
&
Ashish M Kamat The University of Texas Anderson Cancer Center, Department of Urology, Unit 446, 1515 Holcombe Boulevard, Houston, TX 77030, USA. [email protected].
Pages 1047-1056 | Published online: 10 Jan 2014

References

  • Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. JOncol. 19,666–675 (2001).
  • Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 166,490–493 (2001).
  • Pagano F, Bassi P, Galetti TP et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes, and metastases classification. J Urol 145,45–50 (1991).
  • Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vögeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 170,433–437 (2003).
  • •This paper demonstrates the merit of repeat transurethral resection of bladder tumors to improve staging accuracy.
  • May M, Nitzke T, Helke C, Vogler H, Hoschke B. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium of the bladder. Scand. j Urol. Nephrol. 38, 231–235 (2004).
  • Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 163, 1693–1696 (2000).
  • Kim JK, Park SY, Ahn HJ, Kim CS, Cho KS. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 231 (3), 725–731 (2004).
  • Braendengen M, Winderen M, Fossa SD. Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer. Br. J Urol 77(1), 36–40 (1996).
  • Ham SF, Maisey MN. Positron emission tomography for urological tumours. BJU Int. 92(2), 159–164 (2003).
  • Heicappell R, Muller-Mattheis V, Reinhardt M et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[18F]-2-deoxy-D-glucose. Ear. Urol 36(6), 582–587 (1999).
  • Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. j Cilia. Oncol. 19(20), 4005–4013 (2001).
  • •Demonstrates that there is no preferred sequence in combining multiagent chemotherapy with radical cystectomy and bilateral pelvic lymph node dissection.
  • Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Can. Oncol 16(4), 1298–1301 (1998).
  • Amin MB, Ro JY, el-Sharkawy T et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am. J Surg. PathoL 18(12), 1224–1232 (1994).
  • Lopez-Beltran A, Pacelli A, Rothenberg HJ et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. Urol 159(5), 1497–1503 (1998).
  • Siefker-Radtke AO, Dinney CP, Abrahams NA et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience. J Urol 172(2), 481–484 (2004).
  • Bassi P, Ferrante GD, Piazza N et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 161(5), 1494–1497 (1999).
  • Abdel-Latif M, Abol-Enein H, El-Baz M et al. Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol 172(1), 85–89 (2004).
  • Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. [Ira 169(3), 955–960 (2003).
  • Millikan R, Siefker-Radtke A, Grossman HB. Neoadjuvant chemotherapy for bladder cancer. Urol. Oncol 21(6), 464–467 (2003).
  • Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today — a homogenous series without neoadjuvant therapy. Clin. Oncol 21(4), 690–696 (2003).
  • Martinez-Pineiro JA, Gonzalez MM, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized Phase III study. J Urol. 153(3 Pt 2), 964–973 (1995).
  • Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br. J Urol. 67(6), 608–615 (1991).
  • Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Oncol 14(11), 2901–2907 (1996).
  • Bassi P, Pagano F, Pappagallo G et al. Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: the GUONE multicenter Phase III trial. Ear. Urol. 33(Suppl.), 142 (1997) (Abstract 567).
  • Sengelov L, von der Maase H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol 41(5), 447–456 (2002).
  • Abol-Enein H, El-Mekresh M, El-Baz M et al. Neoadjuvant chemotherapy in treatment of invasive transitional bladder cancer. A controlled prospective randomized study. Br. J Urol. 80\(Suppl. 2), 49 (1997) (Abstract 191).
  • Malmstrom P-U, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1.1 UroL 155(6), 1903-1906 (1996).
  • Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin — methotrexate chemotherapy for invasive bladder cancer. Scand. I Urol. Nephrol. 36,419–425 (2002).
  • Grossman HB, Natale R, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl. J. Med. 349,859–866 (2003).
  • •• First to demonstrate improved survival in patients treated with neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) plus cystectomy compared with patients undergoing cystectomy alone.
  • Barjorin D. Plenary debate of randomized Phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Cita Onca 19\(Suppl. 18), 17S-20S (2001).
  • Sternberg CN, Parmar MKB. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Cum Oncol. 19\(Suppl. 18), 21S-26S (2001).
  • EORTC Genito-Urinary Group, Australia Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized trial. Lancet 354, 533–540 (1999).
  • Hall RR. Updated results of randomized controlled trials of neoadjuvant cisplatin (C), methotrexate (M), and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc. Am. Soc. Cum Oncol. 21,178a (2002) (Abstract 710).
  • Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet361, 1927–1934 (2003).
  • ••This landmark meta-analysis is unique inthat the investigators analyzed primary data from individual studies and included data from unpublished studies. The results revealed that neoadjuvant cisplatin-based combination chemotherapy provides a survival advantage over radical cystectomy or radiation therapy alone.
  • Sharif A, Holmberg M, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur. Urol. 45,297–303 (2004).
  • Logothetis CJ, Johnson DE, Chong C et al. Adjuvant chemotherapy of bladder cancer: a preliminary report. J Urol. 139, 1207–1211 (1988).
  • Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J lira 145(3), 459–464 (1991).
  • Shackle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 148, 302–307 (1992).
  • StOckle M, Wellek S, Meyenburg W et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48, 868–875 (1996).
  • Freiha F, Reese J, Torti E A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine, and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 155, 495–500 (1996).
  • Chester JD, Hall GD, Forster M, Protheroe AS. Systemic chemotherapy for patients with bladder cancer — current controversies and future directions. Cancer Treat. Rev. 30, 343–358 (2004).
  • Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann. Onca 11,851–856 (2000).
  • Dimopoulis MA, Moulopoulas LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. JOncol. 16, 1601–1612 (1998).
  • Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.j Clin. Onca 19 (20), 4005–4013 (2001)
  • Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a co-operative group report. J Can. Onca 22 (14), 2781–2789 (2004).
  • •This analysis of the surgical factors from patients enrolled in the Southwest Oncology Group 8710 study revealed that surgical factors influence bladder cancer outcome after cystectomy.
  • Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 171, 1830–1834 (2004).
  • •• The authors present a detailed map of regional lymph node involvement in patients undergoing radical cystectomy and lymphadenectomy for bladder transitional cell carcinoma. Results reveal that an extended lymph node dissection is essential to accurate staging and best therapy.
  • Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin D. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 167, 1295–1298 (2002)
  • Herr HW Superiority of ratio based lymph node staging for bladder cancer. J lira 169,943–945 (2003).
  • Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer. Pharrnacoeconornics 21 (18), 1315–1330 (2003).
  • Lehmann J, Retz M, Stockle M. Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Grit. Rev. Onca Hernata 47,171–179 (2003).
  • von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study.j Cita Onca 17 (17), 3068–3077 (2000).
  • Sacristan JA, Kennedy-Martin T, Rosell R et al. Economic evaluation in a randomized Phase III clinical trial comparing gemcitabineicisplatin and etoposideicisplatin in non-small cell lung cancer. Lung Cancer 28,97–107 (2000).
  • Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 97\(Suppl. 8), 2064–2075 (2003).
  • del Muro XG, Condom E, Vigues F et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100,1859–1867 (2004).
  • de Wit R. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97\(Suppl. 8), 2120–2126 (2003).
  • Crawford ED, Wood DP, Petrylak DP, Scott J, Coltman CA, Raghavan D. Southwest Oncology Group studies in bladder cancer. Cancer 97\(Suppl. 8), 2099–2108 (2003).
  • Raghavan D. Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urol. Oncol. 21, 468–474 (2003).
  • Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Carr. Opin. Onca 16, 257–262 (2004).
  • Small E, Halabi S, Dalbagni G et al. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer 97\(Suppl. 8), 2090–2098 (2003).
  • Bellmunt J, de Wit R, Abiol S, Tabernero J, Albanell J, Baselga J. New drugs and new approaches in metastatic bladder cancer. Grit. Rev. Oncol. Hernatol. 47,195–206 (2003).
  • Dinney CP, McConkey DJ, Milliken RE et al. Focus on bladder cancer. Cancer Cell 6(2), 111–116 (2004).
  • Kamat AM. Neoadjuvant chemotherapy for invasive bladder cancer: a new standard of care? Am. J Clin. Orin Rev. 2, 624–637 (2003).

Websites

  • ACS powerpoint presentation American Cancer Society www.cancer.org/docroot/STT/stt_0.asp (Accessed November 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.